Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

被引：0
|
作者：
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Dena DeMarco
Jingshan Zhang
Jay Mei
Jian Hou
机构：
[1] Guangdong General Hospital,The 1st Affiliated Hospital
[2] Zhejiang University,Department of Hematology
[3] Xiangya Hospital of Central South University,undefined
[4] Peking Union Medical College Hospital,undefined
[5] The 301 Hospital-Chinese PLA General Hospital,undefined
[6] Peking University Third Hospital,undefined
[7] Shanghai 6th Hospital,undefined
[8] The 1st Affiliated Hospital of Soochow University,undefined
[9] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[10] Celgene Corporation,undefined
[11] Shanghai Changzheng Hospital,undefined
来源：
BMC Cancer | / 16卷
关键词：
Relapsed/refractory multiple myeloma; Chinese patients; Lenalidomide; Low-dose dexamethasone; Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Seok Jin Kim
    Danbee Kang
    Yong Park
    Yeung-Chul Mun
    Kihyun Kim
    Jin Seok Kim
    Chang-Ki Min
    Juhee Cho
    Supportive Care in Cancer, 2021, 29 : 4969 - 4977
  • [22] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Kim, Seok Jin
    Kang, Danbee
    Park, Yong
    Mun, Yeung-Chul
    Kim, Kihyun
    Kim, Jin Seok
    Min, Chang-Ki
    Cho, Juhee
    SUPPORTIVE CARE IN CANCER, 2021, 29 (09) : 4969 - 4977
  • [23] LONG TERM TREATMENT WITH LENALIDOMIDE-DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Rocchi, S.
    Petrucci, M. T.
    Zambello, R.
    Montefusco, V.
    Pantani, L.
    Gamberi, B.
    Rizzello, I.
    Nozzoli, C.
    Dozza, L.
    Borsi, E.
    De Paoli, L.
    Palmieri, S.
    Cellini, C.
    di Toritto, T. Caravita
    Tosi, P.
    Morabito, F.
    Gozzetti, A.
    Cavo, M.
    HAEMATOLOGICA, 2017, 102 : 129 - 130
  • [24] Efficacy and Safety Of Lenalidomide Plus Low-Dose Dexamethasone In Chinese Patients With Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment: MM-021 Subgroup Analysis
    Zhou, Dao-Bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    BLOOD, 2013, 122 (21)
  • [25] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
    Siegel, David S.
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Samaras, Christy
    Malek, Ehsan
    Talamo, Giampaolo
    Seet, Christopher S.
    Mouro, Jorge
    Pierceall, William E.
    Zafar, Faiza
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    Bahlis, Nizar J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
  • [26] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Impact of Lenalidomide Plus Low-Dose Dexamethasone Treatment on Immune Cell Populations of the Patients with Refractory/Relapsed Multiple Myeloma
    Lee, Sung-Eun
    Lim, Ji-Young
    Ryu, Da-Bin
    Kim, Tae Woo
    Jeon, Young-Woo
    Yoon, Jae-Ho
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong Wook
    Min, Woo-Sung
    Min, Chang-Ki
    BLOOD, 2015, 126 (23)
  • [28] THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS
    Hou, J.
    Du, X.
    Jin, J.
    Cai, Z.
    Chen, F.
    Zhou, D.
    Yu, L.
    Ke, X.
    Li, X.
    Wu, D.
    Meng, F.
    Ai, H.
    Zhang, J.
    Chen, N.
    Mei, J.
    Wang, J.
    HAEMATOLOGICA, 2013, 98 : 341 - 341
  • [29] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [30] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
12345